All In Biotech

Drug Trial Radar · NCT03832452

A Study in Healthy Subjects to Investigate Whether Administration of Lucerastat Can Affect Normal Heart Function

Prospective, Single-center, Randomized, Double-blind, Placebo-controlled, Two-part Phase 1 Study to Assess the Effect of Single Therapeutic and Supra-therapeutic Doses of Lucerastat on the QT/QTc Interval Duration in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Oct 31, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

44

Actual

Start

Feb 14, 2019

Primary completion

Apr 22, 2019

Study completion Apr 22, 2019

Sponsor

Lead sponsor
Idorsia Pharmaceuticals Ltd.Industry
Sponsor type
Industry
First posted
Feb 6, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Two-part Phase 1 study to assess the effect of single therapeutic and supra-therapeutic doses of lucerastat on the QT/QTc interval duration in healthy subjects (Part A: Pilot study; Part B: TQT study)

Conditions

  • Healthy

Interventions

  • Lucerastat (Treatment A)Drug

    2000 and 4000 mg; hard capsules for oral administration

  • PlaceboOther

    hard capsules for oral administration

  • MoxifloxacinDrug

    400 mg; film-coated tablets for oral administration

  • Lucerastat (Treatment B)Drug

    1000 mg; hard capsules for oral administration

  • Lucerastat (Treatment C)Drug

    4000 mg; hard capsules for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part B: Placebo-corrected, change-from-baseline QTcF (ΔΔQTcF)Time frame: From 1 h pre-dose to 36 hour after study treatment administration (duration: up to 37 hours)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • QPS Netherlands B.V.

    Groningen, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.